以血管生成为分子靶点的放射性核素显像分子探针在肿瘤个体化用药中的应用

刘晓梅; 魏玲格; 张芳; 刘晓梅; 魏玲格; 张芳

doi:10.3760/cma.j.issn.1673-4114.2017.05.011

[1]

Hanahan D, Weinberg RA. Hallmarks of cancer:the next generation[J]. Cell, 2011, 144(5):646-674. DOI:10.1016/j.cell.2011.02.013.

[2]

Moreno Garcia V, Basu B, Molife LR, et al. Combining antiangiogenics to overcome resistance:rationale and clinical experience[J]. Clin Cancer Res, 2012, 18(14):3750-3761. DOI:10.1158/1078-0432.CCR-11-1275.

[3]

Eng L, Azad AK, Habbous S, et al.Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer:a systematic review and meta-analysis[J]. Clin Cancer Res, 2012, 18(17):4526-4537. DOI:10.1158/1078-0432.CCR-12-1315.

[4]

Desar IM, van Herpen CM, van Laarhoven HW, et al. Beyond RECIST:molecular and functional imaging techniques for evaluation of response to targeted therapy[J]. Cancer Treat Rev, 2009, 35(4):309-321. DOI:10.1016/j.ctrv.2008.12.001.

[5]

杨明福, 李前伟.肿瘤血管内皮生长因子受体核素显像研究现状[J].国际放射医学核医学杂志, 2010, 34(1):19-22. DOI:10.3760/cma.j.issn.1673-4114.2010.01.005.
Yang MF, Li QW. Review present study on vascular endothelial growth factor receptor imaging[J]. Int J Radiat Med Nucl Med, 2010, 34(1):19-22. doi: 10.3760/cma.j.issn.1673-4114.2010.01.005

[6]

Cai W, Chen K, Mohamedali KA, et al. PET of vascular endothelial growth factor receptor expression[J]. J Nucl Med, 2006, 47(12):2048-2056.

[7]

Lee I, Yoon KY, Kang CM, et al. Evaluation of the angiogenesis inhibitor KR-31831 in SKOV-3 tumor-bearing mice using 64Cu-DOTA-VEGF121 and micro PET[J]. Nucl Med Biol, 2012, 39(6):840-846. DOI:10.1016/j.nucmedbio.2012.01.007.

[8]

Blankenberg FG, Backer MV, Levashova Z, et al. In vivo tumor angiogenesis imaging with site-specific labeled ^99mTc-HYNIC-VEGF[J]. Eur J Nucl Med Mol Imaging, 2006, 33(7):841-848. DOI:10.1007/s00259-006-0099-1.

[9]

Levashova Z, Backer M, Hamby CV, et al. Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors[J]. J Nucl Med, 2010, 51(6):959-966. DOI:10.2967/jnumed.109.072199.

[10]

Blankenberg FG, Levashova Z, Sarkar SK, et al. Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib:a molecular imaging study[J]. Transl Oncol, 2010, 3(1):56-64. DOI:10.1593/tlo.09271.

[11]

Nagengast WB, Lub-De Hooge MN, Oosting SF, et al. VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment[J]. Cancer Res, 2011, 71(1):143-153. DOI:10.1158/0008-5472.CAN-10-1088.

[12]

Meyer JP, Edwards KJ, Kozlowski P, et al. Selective imaging of VEGFR-1 and VEGFR-2 using 89Zr-labeled single-chain VEGF mutants[J]. J Nucl Med, 2016, 57(11):1811-1816. DOI:10.2967/jnumed.116.173237.

[13]

Stollman TH, Scheer MG, Franssen GM, et al. Tumor accumulation of radiolabeled bevacizumab due to targeting of cell-and matrix-associated VEGF-A isoforms[J]. Cancer Biother Radiopharm, 2009, 24(2):195-200. DOI:10.1089/cbr.2008.0574.

[14]

Scheer MG, Stollman TH, Boerman OC, et al. Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab:Lack of correlation with VEGF-A expression[J]. Eur J Cancer, 2008, 44(13):1835-1840. DOI:10.1016/j.ejca.2008.05.026.

[15]

邵国强, 王自正.整合素αvβ3受体靶向肿瘤显像研究进展[J].国际放射医学核医学杂志, 2014, 38(1):33-36. DOI:10.3760/cma.j.issn.1673-4114.2014.01.007.
Shao GQ, Wang ZZ. Integrin αvβ3 targeted tumor imaging[J]. Int J Radiat Med Nucl Med, 2014, 38(1):33-36. doi: 10.3760/cma.j.issn.1673-4114.2014.01.007

[16]

Axelsson R, Bach-Gansmo T, Castell-Conesa J, et al. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the αvβ3-selective angiogenesis imaging agent ^99mTc-NC100692[J]. Acta Radiol, 2010, 51(1):40-46. DOI:10.3109/02841850903273974.

[17]

Weis SM, Cheresh DA. αv integrins in angiogenesis and cancer[J/OL]. Cold Spring Harb Perspect Med, 2011, 1(1):a006478[2017-01-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234453/.DOI:10.1101/cshperspect.a006478.

[18]

岳宁, 袁双虎, 杨国仁. RGD分子影像在肺癌的研究现状与进展[J].中国肺癌杂志, 2014, 17(12):855-858. DOI:10.3779/j.issn.1009-3419.2014.12.06.
Yue N, Yuan SH, Yang GR. Status and advances of RGD molecular imaging in lung cancer[J]. Chin J Lung Cancer, 2014, 17(12):855-858. doi: 10.3779/j.issn.1009-3419.2014.12.06

[19]

邵国强, 杨瑞, 梁凯, 等. ⁹⁹T^cm-3P4-RGD2 microSPECT/CT显像评价抗新生血管治疗肿瘤疗效价值的实验研究[J].中华放射医学与防护杂志, 2017, 37(1):12-18. DOI:10.3760/cma.j.issn.0254-5098.2017.01.003.
Shao GQ, Yang R, Liang K. Study on ⁹⁹T^cm-3P4-RGD2 micro SPECT/CT imaging to anti-angiogensis therapeutic effect[J]. Chin J Radiol Med Prot, 2017, 37(1):12-18. doi: 10.3760/cma.j.issn.0254-5098.2017.01.003

[20]

Haubner R, Weber WA, Beer AJ, et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and ¹⁸F Galacto-RGD[J/OL]. PLoS One, 2005, 2(3):e70[2017-05-01].http://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.0020070 & type=printable.DOI:10.1371/journal.pmed.0020070.

[21]

Chen H, Niu G, Wu H, et al. Clinical application of radiolabeled RGD peptides for PET imaging of integrin αvβ3[J]. Theranostics, 2016, 6(1):78-92. DOI:10.7150/thno.13242.

[22]

Doss M, Kolb HC, Zhang JJ, et al. Biodistribution and radiation dosimetry of the integrin marker ¹⁸F-RGD-K5 determined from whole-body PET/CT in monkeys and humans[J]. J Nucl Med, 2012, 53(5):787-795. DOI:10.2967/jnumed.111.088955.

[23]

Battle MR, Goggi JL, Allen L, et al.Monitoring tumor response to antiangiogenic sunitinib therapy with ¹⁸F-fluciclatide, an ¹⁸F-labeled αvβ3-integrin and αvβ5-integrin imaging agent[J]. J Nucl Med, 2011, 52(3):424-430. DOI:10.2967/jnumed.110.077479.

[24]

Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled αvβ3 integrin binding peptides in a nude mouse model[J]. Cancer Res, 2002, 62(21):6146-6151.

[25]

Liu S. Radiolabeled cyclic RGD peptide bioconjugates as radiotracers targeting multiple integrins[J]. Bioconjug Chem, 2015, 26(8):1413-1438. DOI:10.1021/acs.bioconjchem.5b00327.

[26]

Wang K, Seo BR, Fischbach C, et al. Fibronectin mechanobiology regulates tumorigenesis[J]. Cell Mol Bioeng, 2016, 9:1-11. DOI:10.1007/s12195-015-0417-4.

[27]

Berndorff D, Borkowski S, Moosmayer D, et al. Imaging of tumor angiogenesis using ^99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments[J]. J Nucl Med, 2006, 47(10):1707-1716.

[28]

Yoshimoto M, Kurihara H, Fujii H, et al. Theragnostic imaging using radiolabeled antibodies and tyrosine kinase inhibitors[J/OL]. Scientific World J, 2015, 2015:842101[2017-05-01]. https://www.researchgate.net/publication/276159365_Theragnostic_Imaging_Using_Radiolabeled_Antibodies_and_Tyrosine_Kinase_Inhibitors.DOI:10.1155/2015/842101.

[29]

Jung KH, Lee KH. Molecular imaging in the era of personalized medicine[J]. J Pathol Transl Med, 2015, 49(1):5-12. DOI:10.4132/jptm.2014.10.24.

[30]

Mees G, Dierckx R, Mertens K, et al. ^99mTc-labeled t ricarbonyl his-CNA35 as an imaging agent for the detection of tumor vasculature[J]. J Nucl Med, 2012, 53(3):464-471. DOI:10.2967/jnumed.111. 095794.